Higher urinary bisphenol A concentration is associated with unexplained recurrent miscarriage risk: evidence from a case-control study in eastern China.

BACKGROUND: Evidence about the association between Bisphenol A (BPA) and the risk of recurrent miscarriage (RM) in human being is still limited.
OBJECTIVE: We evaluated the association of urinary BPA concentrations with RM in human being.
METHODS: A hospital-based 1:2 matched case-control study on RM was carried out in Suzhou and Kunshan in Jiangsu Province in China between August 2008 and November 2011. Total urinary BPA concentrations in 264 eligible urine samples (102 RM patients and 162 controls) were measured using liquid chromatography-tandem mass spectrometry (LC-MS/MS). The Wilcoxon test and conditional logistic regression were used to estimate the differences between the groups and odds ratios (OR) with 95% confidence intervals (CI), respectively.
RESULTS: The median ± IQR (interquartile range) (P75-P25) values of non-creatinine-adjusted total urinary BPA levels in the RM patients and the controls were 1.66 ± 3.69 ng/ml and 0.58 ± 1.07 ng/ml, respectively (0.98 ± 2.67 μg/g Cr (creatinine) and 0.40 ± 0.77 μg/g Cr. The adjusted BPA level was significantly higher in the RM patients than in the controls (Wilcoxon test, Z = 4.476, P < 0.001). Higher level of urinary BPA was significantly associated with an increased risk of RM (P-trend < 0.001). Compared to the groups with urinary BPA levels less than 0.16 μg/g Cr, the women with levels of 0.40-0.93 μg/g Cr and 0.93 μg/g Cr or above had a significantly higher risk of RM (OR = 3.91, 95%CI: 1.23-12.45 and OR = 9.34, 95%CI: 3.06-28.44) that persisted after adjusting for confounding factors. The time from recently RM date to recruitment does not significantly influence the urinary BPA level (P = 0.090).
CONCLUSION: Exposure to BPA may be associated with RM risk.

Introduction

Recurrent miscarriage (RM) has traditionally been defined as three consecutive unexplained terminations of pregnancy before 20 weeks of gestation or expulsions of a fetus weighing<500g [1]. The prevalence of RM has been reported to be as high as 0.5–3% [2, 3]. There is a tendency to expand this definition to include women who have experienced only two miscarriages, particularly in studies focusing on the aetiology or risk factors of RM [1, 4]. The causes of RM are very complicated. The identifiable factors of RM may include parental chromosomal anomalies, uterine pathology, a prothrombotic state, endocrine disorders, immunological factors, and infections [5-10]. However, the causes of RM remain unexplained for approximately half of the women who experience RM, despite thorough investigations [4].

Currently, endocrine-disrupting chemicals (EDCs), including bisphenol A (BPA), polychlorinated biphenyls (PCBs), 1,1-dichloro-2,2-bis(p-chlorophenyl) ethylene (DDE) and hexachlorobenzene (HCB), are the most prominent potential causes of unexplained RM [11, 12]. BPA, a monomer used in the production of polycarbonates and epoxy resins and as an antioxidant in PVC plastics, is one of the most widely used industrial compounds worldwide. In general, polycarbonates are used to manufacture plastic food containers and the epoxy resins that coat the inner surfaces of food and beverage cans. PVC is used in a variety of products, including materials that may come into contact with food, such as plastic film used for packaging food. The migration of BPA from polycarbonate plastics, surfaces of epoxy-coated cans, and PVC products into food and food stimulants has been reported, especially when heated [13-15]. Humans may be exposed to BPA in food, beverages, dust, etc. BPA is a well-known endocrine disruptor with estrogenic and anti-androgen activities that can cause a variety of adverse effects in both animals and humans. Evidence from large experimental studies suggests that exposure to BPA has adverse effects on reproductive development in animals [16-21], and recently there two epidemiologic studies on the association between BPA exposure and miscarriage risk [22, 23], but human studies on the BPA associated with RM risk are still limited. Urinary BPA may be associated with lower semen quality, increased sperm DNA damage [24], and self-reported sexual dysfunction in males [25]. Bloom and colleagues assessed BPA in couples undergoing in vitro fertilization (IVF) and measured indicators of embryo quality. The study showed that male BPA exposure may affect embryo quality by influencing the early embryo cleavage rate during IVF [26]. Several studies found that serum BPA levels were associated with endometrial hyperplasia and ovarian dysfunction in females [27-29]. To date, only one study from Japan has reported findings about the relationship between serum BPA levels and RM [11].

We measured the total urinary BPA level (conjugated and free) to quantify the amount of human exposure to BPA. Although BPA has a short half-life in biological tissues [30, 31], urinary BPA is still considered to be the preferred indicator to assess biological exposure [32].

Suzhou and neighboring Kunshan cities are located in the lower reaches of the Yangtze River––the most industrialized areas in eastern China. After 30 years of rapid economic development and marked life style changes, environment challenges in this area on public health such as plasticizer use and other endocrine disrupting chemicals should be examined. The aim of the present study is to investigate the association between urinary BPA levels and unexplained RM, a relationship that has not yet been reported.

Methods

Subjects and recruitment

First, between August 2008 and November 2011, we initially registered 121 patients aged 20–40 years who sought treatment and self-reported history of RM with repeated (2–6 RMs), consecutive unexplained terminations of pregnancy before 20 weeks of gestation from the outpatients of obstetric and gynaecological clinics of three hospitals––the Maternal and Child Health Center in Kunshan City, the First People's Hospital, and the Second People's Hospital affiliated with Soochow University. The time from the nearest RM date for the patients to recruitment were various from 2 days to 352 days. The patients were asked to answer questionnaire, provide morning spot urine and blood samples less than two weeks after the recruitment. They also completed regular medical examination (B-mode ultrasound, autoimmune disorder test, and abnormal coagulate function test) to exclude other known causes of RM.

When the study was completed, 19 cases were excluded for the exclusion criteria including reproductive system malformation (uterus bicornis, uterus septus, uterine leiomyoma) (8), autoimmune disorders (anticardiolipin antibody- and antinuclear antibody-positive) (6) and abnormal coagulate function (5). We have not excluded the patients who suffered chromosome abnormalities and endocrine disorders. In each hospital, there are more than 20 pregnant women performing the routine prenatal examination in every working day, who were registered their name, age and gestational age, etc. Once acquired one eligible RM case, based on the prenatal examination name list, we tried to match 2 controls of pregnant women aged 20–40 years with no history of miscarriage in the same hospital with the following criteria: age (±2 years), gestational age (±1 week), and living in the same district. We excluded the controls who had a history of pregnancy complications, miscarriage, still birth or pre-eclampsia, and none had given birth to a small for gestational age infant. Totally 60 cases were successfully matched 2 controls, however 42 cases only had 1 match.

The controls were also asked to provide information on demographic characteristics, lifestyle, obstetric history, and other RM risk factors by a structured questionnaire and morning spot urine and blood samples. To avoid contamination from plastic equipment, glass containers were used in the sampling and experimental processes. The containers were soaked in nitric acid solution for at least 12h, washed with deionised water, and baked at 70°C for at least 10h. The urine samples were stored at -80°C before LC-MS/MS analysis. Written informed consent was obtained from each participant. The study was approved by the ethics committee of Soochow University.

Analysis of Urinary BPA

LC-MS/MS was used to measure total BPA (conjugated and free) in the urine samples from the participants, using selective reaction monitoring (SRM). After pre-treatment, the samples (25μl) were separated by a BR-C18 column (5μm, 100×2.1mm; Sepax, USA) using a Thermo Finnigan high performance liquid chromatography system combined with a TSQ Quantum Ultra triple quadrupole tandem mass spectrometer (Thermo Electron, Waltham, MA, USA) equipped with an electrospray ionization probe (Thermo Electron). Gradient elution with a 0.3% ammonia solution (solvent A) and methanol (solvent B) was carried out using the following procedure: 40% B for 0.5min, gradually increased to 95% B within 2min, solvent composition held at 95% B for 1.5min and equilibrated at 40% B for 1.5min. The total chromatographic separation time was 5.5min. The flow rate was 300μl/min. To record spectral data, a vaporizer temperature of 300°C and a TurboIonSpray voltage of -3.0kV in the negative ionization mode were applied. Nitrogen served as the sheath gas, the auxiliary gas, and the ion sweep gas; the values of these gases were set to 50, 10, and 1 arbitrary unit(s), respectively. The mass spectrometer was operated in the selected reaction monitoring (SRM) mode with a signal time segment. The scan width for SRM was 0.01m/z, scan time was 0.1s, and the peak width settings (FWHM) for both Q1 and Q3 were 0.7.

The pre-treatment process was a modified version of the methods used by Matsumoto [33]. Urine (500μl) and 50μl d16-BPA 200ng/ml (internal standard) were buffered with 350μl of 1.0 M sodium acetate buffer (pH5.0) and hydrolysed enzymatically with β-glucuronidase/sulfatase(110,000U/ml/4,000U/ml, Sigma Chemical Co., USA) at 37°C overnight in a shaking water bath [34]. After hydrolysis, the hydrolysate was extracted once with 5ml of ethyl acetate. After centrifugation, the supernatant was transferred to a new glass tube and evaporated with N2 gas. The residue was dissolved with 500μl of 30/70 (v/v) methanol/water solution, filtered using a microporous membrane filter and injected into the LC-MS/MS system described above.

The standard curve of this method was y = 0.1304+0.6801x. Satisfactory linearity was obtained (r>0.999). The limit of detection (LOD) of urinary BPA was 0.20ng/ml, similar other studies [35, 36]. Recoveries of BPA ranged from 105.0% to 109.5%. The repeatability of the method was evaluated by analysing six replicates of four samples spiked with standard BPA. Expressed as the relative standard deviation (RSD) within each day and between days, the values were calculated as 3.16%-4.22% and 5.22%-5.30%, respectively. Fig 1 showed the chromatograms of standard, case and control urine samples, which had concentrations of 1ng/ml, 0.7ng/ml and 0.61ng/ml, respectively. BPA levels were measured by comparing the retention time to the retention time of the main peak (3.6min) in the chromatogram of standard BPA. To measure BPA concentration, a mean blank value of 0.4ng/ml had been determined and was subtracted from each measured value. In addition, the BPA value was adjusted for the urinary creatinine concentration to correct for the urine volume. Creatinine was detected using the method of measuring enzymatic creatinine in an automatic biochemical instrument (Hitachi 7020). The concentration of urinary BPA was expressed in micrograms of BPA per gram of creatinine.

Fig 1

Chromatogram of BPA standard (1ng/ml) (a), one RM patient’s urine sample (0.7ng/ml) (b) and one control patient’s urine sample (0.61ng/ml) (c).

Statistical analysis

We imputed the missing levels by the value of the LOD divided by the square root of 2 if the geometric standard deviation (GSD) was less than 3; otherwise, we imputed by the LOD divided by 2 [35, 37]. We used the Wilcoxon method to compare the difference in urinary BPA levels between RM patients and controls or between other different groups because the urinary BPA levels of the patients in the two groups were not normally distributed. Univariate and multivariate conditional logistic regression were used to calculate crude and adjusted ORs (95%CI), respectively, to estimate the association between urinary BPA and RM. Potential confounders include age, occupation, years of education, BMI and passive smoking during pregnancy in our study. Statistical power was calculated using SAS Proc power. On the basis of prevalence of urinary BPA ≤0.16 μg/g Cr in 25% of general women population and a ratio of two control subjects to 1 case, 102 cases and 162 control subjects has 92.7% power to detect an odds ratio of 2.5. The significance level was set at P<0.05 for all tests. SAS 9.2 software (SAS Institute, Inc., Cary, NC) was used for all analyses.

Results

Characteristics of subjects

The mean age ± SD of the RM patients was 28.04±3.68 years, and the mean age of the controls was 28.36±3.75 years. On average, the women in the case group had experienced 2.47 previous miscarriages (2 to 6 RMs), some consecutively and some not consecutively but at least 2 consecutive. There were no significant differences in age or occupation between the case and control groups (P>0.05). However, BMI on average was significantly lower among the controls than among the RM patients (P<0.001). The distributions of BMI and the years of education of the two groups were significantly different (P = 0.047 and P = 0.001, respectively) (Table 1).

Table 1

Demographic characteristics of the RM patients and the controls*.

	RM patients(102)	Controls(162)	P-values
Age	28.36±3.75	28.04±3.68	0.351
No.of RM	2.47±0.73	-
BMI	21.18±2.29	20.19±2.37	<0.001
	n (%)	n (%)
Age
<25	18(17.65)	25(15.43)	0.256
25~29	43(42.16)	85(52.47)
>29	41(40.20)	52(32.10)
BMI (kg/m 2 )
<18.5	11(10.78)	36(22.22)	0.047
18.5~	78(76.47)	116(71.60)
24~	12(11.76)	9(5.56)
≥28	1(0.98)	1(0.62)
Years of education
≤6	23(22.55)	25(15.43)	0.001
7~9	24(23.53)	58(35.80)
10~12	23(22.55)	56(34.57)
>12	32(31.37)	23(14.20)
Occupation
Workers	15(14.71)	26(16.05)	0.593
Business/services	31(30.39)	57(35.19)
Professionals	24(23.53)	25(15.43)
Unemployed	23(22.55)	39(24.07)
Other	9(8.82)	4(9.26)

*The values for age, number of RM and BMI are expressed as the mean ± SD. BMI = body mass index (kg/m2).

Urinary BPA concentration in RM patients and controls

Fig 2 shows the distributions of non-creatinine-adjusted and creatinine-adjusted urinary BPA in the RM patients and the controls. No significant differences in the detection rate of urinary BPA were found between the RM patients (85.29%) and the controls (82.10%) (P = 0.498). Without adjusting for creatinine, the median ± IQR value of total urinary BPA levels in the RM patients was 1.66±3.69ng/ml, significantly higher than the level measured in the controls (0.58±1.07ng/ml) (P<0.001). After adjusting for creatinine, the median ± quartile range urinary BPA level among the RM patients was 0.98±2.67μg/g Cr, significantly higher than the level among the controls (0.40±0.77μg/g Cr) (P<0.001). Significant differences can be observed between cases and controls in the subgroups defined by age, BMI, years of education, occupation and passive smoking during pregnancy (P<0.05). However, for the same RM patients group or the same controls group, we did not find that the age, BMI, years of education, occupation and passive smoking status significantly were associated with the creatinine-adjusted BPA level (all P>0.05) (Table 2).

Fig 2

Distribution of non-creatinine-adjusted (a) and creatinine-adjusted (b) urinary BPA concentration in the RM patients and the controls.

Table 2

Creatinine-adjusted urinary BPA concentration in the RM patients and the controls (μg/g Cr).

	RM patients(102)		Controls(162)		P-values
	n(Detection rate)*	Median (P 25-P 75) (μg/g Cr)	n(Detection rate) *	Median(P 25-P 75) (μg/g Cr)
Age Age(years)
<25	18(88.89)	0.55(0.32–4.17)	25(88.00)	0.47(0.26–1.44)	0.242
25~29	43(86.05)	1.74(0.24–4.22)	85(84.71)	0.40(0.16–0.97)	0.001
>29	41(82.93)	0.85(0.43–1.65)	52(75.00)	0.37(0.14–0.73)	0.001
P-values		0.216		0.311
BMI
<18.5	11(81.82)	0.51(0.19–3.61)	36(75.00)	0.37(0.14–0.82)	0.156
18.5~	78(85.90)	1.19(0.35–3.02)	116(85.34)	0.46(0.17–0.97)	<0.001
24~31	13(84.62)	0.95(0.44–1.66)	10(70.00)	0.21(0.16–0.52)	0.017
P-values		0.899		0.557
Years of education
≤6	23(91.30)	1.12(0.42–2.49)	25(88.00)	0.46(0.26–0.88)	0.041
7~9	24(83.33)	1.63(0.33–3.89)	58(79.31)	0.39(0.14–0.73)	0.002
10~12	23(86.96)	1.33(0.44–5.34)	56(85.71)	0.52(0.21–1.60)	0.050
>12	32(81.25)	0.72(0.29–2.13)	23(73.91)	0.30(0.13–0.57)	0.015
P-values		0.491		0.136
Occupation
Workers	15(93.33)	0.55(0.41–5.25)	26(69.23)	0.38(0.16–0.75)	0.021
Business/services	31(90.32)	1.33(0.34–3.61)	57(84.21)	0.50(0.14–0.97)	0.014
Professionals	24(83.33)	0.90(0.31–2.19)	25(76.00)	0.38(0.14–0.90)	0.027
Unemployed	23(73.91)	0.54(0.32–2.49)	39(94.87)	0.40(0.21–0.73)	0.080
Other	9(88.89)	1.66(0.60–4.69)	15(73.33)	0.32(0.17–2.26)	0.190
P-values		0.767		0.970
Passive Smoking
No	76(82.89)	1.23(0.40–3.05)	128(82.81)	0.39(0.16–0.80)	<0.001
Yes	26(92.31)	0.55(0.34–2.80)	34(79.41)	0.42(0.17–1.55)	0.236
P-values		0.348		0.438
Total	102(85.29)	0.98(0.35–3.02)	162(82.10)	0.40(0.16–0.93)	<0.001
		1.66(0.49–4.18) #		0.58(0.24–1.31) #	<0.001

* n = detection of total number.

# The median ± IQR values of non-creatinine-adjusted total urinary BPA levels in the RM patients and the controls

Association between urinary BPA level and RM

In the model, BPA levels were categorized into four groups: ≤P , P -≤P , P -P , >P of the control group BPA concentration. After adjusting for occupation, years of education, BMI, passive smoking during pregnancy, higher urinary BPA levels were associated with an increased risk of RM (P-trend<0.001). Compared to the group with urinary BPA level≤0.16μg/g Cr, the RM odds ratios for the groups with BPA levels of 0.16–0.40μg/g Cr, 0.40–0.93μg/g Cr and >0.93μg/g Cr were 2.90 (95%CI: 0.93–9.03), 3.91(95%CI:1.23–12.45), and 9.34 (95%CI: 3.06–28.44), respectively (Table 3). In addition, though significant difference for creatinine-adjusted BPA level was found between three kinds of women with 0, 2 times and >2 times RM history (P<0.001), no dose-response relationship existed between the RM times and BPA levels (Table 4).

Table 3

Association between urinary BPA level and RM.

Urinary BPA Concentration (μg/g Cr)	RM patients (%)	Controls(%)	OR(95%CI)	OR* (95%CI)	P-values
≤0.16	7(6.86)	41(25.31)	1.0	1.0
0.16~	20(19.61)	40(24.69)	3.10(1.07–9.01)	2.90(0.93–9.03)	0.067
0.40~	22(21.57)	41(25.31)	3.71(1.27–10.85)	3.91(1.23–12.45)	0.021
>0.93	53(51.96)	40(24.69)	9.64(3.35–27.74)	9.34(3.06–28.44)	<0.001
Trend test					<0.001
age				2.25(0.97–1.62)	0.085
occupation,				1.03(0.82–1.29)	0.791
years of education				1.22(0.89–1.68)	0.213
BMI				1.23(1.05–1.44)	0.010
passive smoking				2.98(0.73–12.21)	0.130

*Adjusted for age, occupation, years of education, BMI, passive smoking during pregnancy

Table 4

Distribution of urinary BPA levels in controls, two and three or more RM patients.

	n(Detection rate)*	Median(P25-P75) (ng/ml)	Median(P 25-P 75) † (μg/g Cr)	F-value	P-value #
Controls	162(82.10)	0.58(0.24–1.31) b	0.40(0.16–0.93) b	12.46	<0.001
Two RMs	64(90.63)	2.01(0.57–5.26) a	1.35(0.43–3.35) a
≥Three RMs	38(76.32)	0.95(0.22–2.38) b	0.60(0.32–1.97) a

* n = detection of total number

Adjustment for creatinine-adjusted BPA

# for creatinine-adjusted BPA

a, b: In the method of SNK analysis, there was not statistically significant difference with the same letters (a, b) (P>0.05); There was statistically significant difference with the different letters (a, b) (P <0.05).

Association between time from recently RM date to recruitment and urinary BPA level

There was no significant difference for the median creatinine-adjusted urinary BPA concentration (μg/g Cr) among the different groups of time from recently RM date to recruitment (Wilcoxon χ2 = 6.48, P = 0.090) (Table 5). No significant rank correlation was found between the duration from RM date to recruitment and urinary BPA level (Spearman correlation coefficient rs = -0.081, P = 0.421).

Table 5

Time from recently RM date to recruitment and creatinine-adjusted urinary BPA concentration (μg/g Cr)*.

Time from RM date to recruitment (days)	Mean±SD(n)	Median (P 25-P 75)	Min	Max
≤5	11.93±51.29(26)	0.45(0.32,1.66)	0.10	262.46
6~18	10.42±36.80(25)	1.15(0.51,3.68)	0.26	185.26
19~114	1.50±1.76(26)	0.78(0.32,1.88)	0.02	6.79
115~352	3.09±3.48(25)	1.69(0.72,4.22)	0.05	10.93

* Wilcoxon χ2 = 6.48, P = 0.090

Discussion

In the present study, we found that the urinary BPA level of women who have experienced RM was significantly higher than the level measured in controls. The higher the urinary BPA levels of the women were, the stronger RM risk of 3~9 times was suggested. The time from recently RM date to recruitment does not influence the urinary BPA level, which has not been reported previously. The detection rates of urinary BPA reported in other countries range from 52% to 100% [38]. We found a reasonably similar detection rate in our study. The BPA level in our study was comparable to three previous studies [35, 39, 40] that reported median urinary BPA concentrations of 1.2μg/l, 1.3μg/l, and 1.2μg/l, respectively. After adjusting for creatinine, the BPA level was a little lower than two previous studies [31, 40] that reported median BPA levels of 1.7μg/g Cr and 2.2μg/g Cr, respectively. One study of a Chinese population without occupational exposure found a median urinary BPA concentration level below the LOD (0.31μg/l) [32]; the median urinary BPA of the controls in our study was 0.58ng/ml, slightly higher than the BPA level He reported. However, exposure to BPA is related to the changes in lifestyle in recent years. Thus, the exposure level to BPA may be different in different regions and over time [41-43].

To the best of our knowledge, this is the first epidemiologic study to investigate the association between urinary BPA level and RM risk in humans using a relatively large sample. The strengths of our methods also include the addition of an internal standard (d16-BPA), the relatively low limit of BPA detection and the adjustment of urinary BPA concentration by creatinine. In addition, we controlled the BMI variable in the logistic model, which was reported to be significantly associated with RM risk [44, 45].

Through two studies have been reported the association between the BPA exposure and miscarriage in women, the conclusion is inconsistent [22, 23]. To date, only Sugiura-Ogasawara and colleagues [11] have examined serum BPA levels using ELISA in 45 patients with a history of three or more (3–11) consecutive first-trimester miscarriages and 32 healthy women who had never given birth and had no history of infertility. The mean ± SD level of BPA in the patients was 2.59±5.23ng/ml, significantly higher than the level found in the controls (0.77±0.38ng/ml) (P = 0.024). This study suggested that high exposure to BPA may be associated with RM. Our results provided a different exposure biomarker in support of this conclusion.

Our findings were supported from animal and other human studies. It is clear that BPA has adverse effects on reproduction for animals in vitro and in vivo [17, 46, 47]. Lemos and colleagues showed that the success to achieve pregnancy decreased slightly with BPA concentration increasing in the terrestrial isopod Porcellio scaber, and there were 20% more miscarriages after exposure to 10 and 1000 mg BPA kg-1 dry soil [48]. In addition, an important study from China [19] found that zebrafish embryos exposed to BPA in early embryonic development exhibited higher levels of bioaccumulation and toxicity of BPA than in late embryonic development; they were also more likely to experience lethal or sublethal toxicity. For humans, BPA is a well- studied, well characterized, ubiquitous EDC. Previous studies demonstrated that serum BPA levels were associated with endometrial hyperplasia and ovarian dysfunction in females [27-29]. Balakrishnan and colleagues have demonstrated that BPA at low environmentally relevant levels can transfer across the human placenta [49]. What’s more, Nishikawa found that BPA‑GA is transferred into the fetus and deconjugated in the fetus [50]. There was a particularly worrying finding that human fetuses have also been contaminated with BPA [51, 52]. Serum BPA levels among women carrying fetuses with an abnormal karyotype were higher than the levels in women carrying fetuses with a normal karyotype [53]. In addition, a study found that there was a positive linear dose-response association between urinary BPA concentrations and implantation failure among women undergoing in vitro fertilization [54].

The major limitation of our study is that the BPA measurements were based on a spot urine sample. We could not acquire samples before or during the RM patients’ pregnancies, although this could have provided information about women’s daily BPA exposure during the critical period. Urinary BPA concentration has a moderate degree of intra-individual variability, making it difficult to accurately characterize exposure from a single measurement [31]. Braun et al. also mentioned that more than one sample may be necessary for BPA during pregnancy [55]. However, it has been reported that a single sample is predictive of BPA exposure over weeks or months, and a single sample can provide good sensitivity to classify a person’s exposure in epidemiologic studies [34, 56, 57]. Therefore, the urine samples we collected should be partly representative of the daily BPA exposure level of the subjects. An additional limitation is that the cases were not pregnant at the time of urine sample collection while the controls were. It cannot be excluded that the differences in BPA concentration between patients and controls could partly be due to one group being pregnant and the other not. There is recent evidence showing that serial urine concentrations of BPA were highly variable before and during pregnancy, these pregnancy induced changes may influence the absorption, distribution, metabolism, or excretion of BPA [55]. But, due to the limitation of the field conditions, we had difficulty to collect urine sample from the cases before or at the time of miscarriage. To resolve this problem, we consider to design a cohort study and to collect specimens according to the monitoring data in the future research. In this study, although we did not collect information about women chromosome abnormality and maternal endocrinologic disorders, because there is no evidence that the BPA level is associated with chromosome abnormalities and endocrine disorders, if the cases included a little number of such women, it would have underestimated the OR between the exposure and outcome. Calafat reported that BPA was associated with the use of medical devices [58]. Hence, our evidence need further studies in consideration of the medical devices, though according to our investigation of gynaecologists and obstetricians, most subjects who visited hospitals for RM were generally not treated with intravenous or intramuscular injections; instead, they were prescribed traditional Chinese medicine remedies for improving their endocrine secretion.

The biological mechanism of our findings and the above results of animals and human studies may be relevant to the chemical structure of BPA. It is similar to that of endogenous estrogens and can mimic the function of 17β-estradiol (E2) by combining with the estrogen receptors. So BPA can interfere with normal levels of hormones in the blood and functioning of estrogens, and further affect the reproductive development [55].

In conclusion, higher daily exposure to BPA was associated with an increased risk of RM, and that longitudinal studies are required to investigate the association between maternal BPA levels during pregnancy and RM.